Recipharm appoints Bernard Pluta President, Development Services

Amy Schofield 15 February 2018

Contract development and manufacturing organisation (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organisation.

The newly established position forms part of the ongoing transformation of Recipharm’s Development Services, in which a total of 400 employees across six countries are united to deliver a comprehensive development offering.

The scientific, chemical and pharmaceutical expertise will cover end-to-end development services, ranging from development of the active compound to providing dossiers for marketing authorisation applications in all major geographies. The combined capabilities and capacities will provide the CDMO’s customers with an efficient pathway to commercialisation.

Pluta is currently the General Manager of Recipharm’s manufacturing and development operations in Pessac, France and recently led a group-wide project focussing on optimising and coordinating Recipharm’s extensive development capacities in Sweden, Italy, France, US, India and Israel.

Pluta has strong experience in the pharma and CDMO industry having held executive positions with Theramex, Merck Serono and Teva. He also ran his own CMO consultancy business before joining Recipharm in 2015 and holds a dual degree as Industrial Engineer and MBA. In his role as President, Development Services, he will report to CEO Thomas Eldered and be a part of the group management team.

Pluta will continue as General Manager of Recipharm in Pessac until a successor has been appointed.

Recipharm’s new development organisation will be implemented during the first half of 2018. Development services will continue to be reported as part of Recipharm’s Development & Technology segment.

Eldered said: “Bernard has managed our operations in Pessac with great success. His industry expertise and solid business competence will play a key role in transforming our development services and ensuring a seamless end-to-end offering. By providing a wide range of development services we are well positioned to manage challenging projects and complexity on behalf of our customers.”


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.